MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$18,825,916
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from issuance of debent...
    • Represents the amount of proceed...
    • Increase (decrease) in accounts ...
    • Others
Negative Cash Flow Breakdown
    • Repayment of debenture
    • Prepaid expenses
    • Increase (decrease) in accounts ...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Represents the amount of change in fair value of debentures
-
-
0
383,823
Repayment of debentures on extinguishment
-
-
0
-25,000
Represents the amount of increase decrease in costs related to settlements
-
-
0
300,000
Represents the amount of costs to issue debentures
-
-
0
0
Research and development expense (excluding acquired in process cost)
-
-
0
8,717,475
Net loss for the period
-11,684,427
-9,042,311
-8,184,557
-27,259,804
Foreign exchange gain/loss
-
-
-33,131
-8,816
Stock-based compensation expense
1,405,826
599,306
429,712
852,757
Paid-in-kind interest
101,340
379,254
339,381
89,680
Represents the amount of operating lease right-of-use assets
27,147
26,402
25,516
24,750
Represents the amount of gain loss on settlements
0
-127,083
-121,133
-157,721
Represents the amount of change in fair value of debentures and secured promissory notes
0
-
-
-
Represents the amount of costs to issue debentures and secured promissory notes
0
-
-
-
Represent the amount of issuance of common shares in connection with non-cash compensation for services rendered
378,070
-
-
-
Prepaid expenses
876,667
-169,351
-35,303
-430,723
Deferred financing costs
-
-
99,305
0
Increase (decrease) in accounts payable, trade
4,411,457
-1,263,656
1,303,585
-380,033
Increase (decrease) in accounts payable and accrued liabilities
-724,721
44,650
-549,969
-954,308
Increase (decrease) in operating lease liability
-36,091
-40,514
-36,441
-50,058
Increase (decrease) in accounts payable, related parties
14,623
30,747
-26,604
21,807
Net cash used in operating activities
-6,983,441
-8,969,688
-6,609,115
-6,757,829
Proceeds from convertible debt
-
-
0
0
Proceeds from issuance initial public offering
-
-
0
-
Proceeds from issuance of common stock
0
0
0
9,790,015
Proceeds from issuance of debentures
22,000,000
-
0
7,366,293
Proceeds from warrant exercises
0
-
5,145,600
3,752,000
Proceeds from stock options exercised
-
-
0
162,400
Cost to issue debentures and secured promissory notes
615,000
-
0
136,726
Cash paid for financing costs in connection with sepa
0
-297,783
-
-
Repayment of debenture
2,347,705
3,184,908
1,753,398
5,637,709
Represents the amount of proceeds from issuance of shares under settlements
0
4,102,740
3,330,411
5,097,005
Issuance costs for common shares
-
-
69,143
584,361
Represents the amount of proceeds from issuance of common stock at the market offering net of issuance costs
18,307,134
-5,907,319
-
-
Net cash provided by financing activities
25,529,791
6,825,151
6,653,470
10,371,267
Represents the amount of net cash paid for antev asset acquisition including transaction costs
-
-
0
4,619,152
Cash provided by (used in) investing activity, including discontinued operation
-
-
0
-4,619,152
Effect of exchange rate on cash, cash equivalent, restricted cash, and restricted cash equivalent, continuing operation
279,566
-195,057
-1,228
-1,741
Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation
18,825,916
-2,339,594
43,127
4,497,768
Cash and cash equivalents and restricted cash, end of the period
6,365,624
8,705,218
8,662,091
4,164,323
Cash and cash equivalents and restricted cash, end of the period
25,191,540
6,365,624
8,705,218
8,662,091
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofdebentures$22,000,000 (388.89%↑ Y/Y)Represents the amount ofproceeds from issuance of...$18,307,134 Net cash provided byfinancing activities$25,529,791 (71.17%↑ Y/Y)Effect of exchange rateon cash, cash...$279,566 Canceled cashflow$14,777,343 Cash, cashequivalent, restricted...$18,825,916 Canceled cashflow$6,983,441 something is missing-$11,814,638 Repayment of debenture$2,347,705 Cost to issuedebentures and secured...$615,000 Increase (decrease) inaccounts payable, trade$4,411,457 Stock-based compensationexpense$1,405,826 (511.96%↑ Y/Y)Represent the amount ofissuance of common shares...$378,070 Paid-in-kind interest$101,340 Represents the amount ofoperating lease...$27,147 (-42.93%↓ Y/Y)Increase (decrease) inaccounts payable,...$14,623 (169.02%↑ Y/Y)Net cash used inoperating activities-$6,983,441 (25.79%↑ Y/Y)Canceled cashflow$6,338,463 Net loss for theperiod-$11,684,427 Prepaid expenses$876,667 (674.43%↑ Y/Y)Increase (decrease) inaccounts payable and...-$724,721 (-168.02%↓ Y/Y)Increase (decrease) inoperating lease liability-$36,091 (35.68%↑ Y/Y)

Medicus Pharma Ltd. (MDCXW)

Medicus Pharma Ltd. (MDCXW)